SAN FRANCISCO — PlenOptika's handheld, AI-powered vision diagnostic tools, QuickSee Free and QuickSee Free Pro, have enabled more than 10 million patient interactions globally since their launch in late 2023, operating in over 65 countries.
The devices perform automated vision assessments—known as objective refraction—outside traditional clinical settings. That capability addresses a concrete market failure: an estimated one billion people lack access to corrective eyeglasses, driven by a shortage of eye care providers and fixed clinic infrastructure.
Development of PlenOptika's second-generation autorefractor technology received funding from the Translational Research Institute for Space Health (TRISH), which focuses on medical devices that perform in extreme conditions.
The company has structured its go-to-market around partnerships with healthcare providers, governments, nonprofits and global health organizations—a distribution strategy that avoids the capital cost of building owned clinical networks. The Fred Hollows Foundation, Sightsavers and Orbis International have used QuickSee Free in screening programs across Nepal, Sierra Leone, Mongolia, Uganda and India.
The device also deployed during the Polaris Dawn mission, validating its performance in autonomous, resource-constrained environments relevant to long-duration space exploration.
"TRISH inspired and supported innovation in our medical devices," said Dr. Shivang R. Dave, PlenOptika co-founder and CEO. "The goal was to deliver clinical quality results in the toughest conditions—directly benefiting the billion people living with refractive error on Earth."
PlenOptika's competitive position rests on accuracy and portability in a single device. That combination enables a distributed care model: no fixed infrastructure, no specialist required, lower cost per patient. In markets where traditional optical clinics are economically or geographically out of reach, that unit economics advantage is the market entry.
The partnership-led scaling strategy is also capital-efficient—PlenOptika uses established NGO and government networks to reach large patient populations rather than funding its own outreach operations.
Each deployment adds to a growing dataset that tightens the underlying AI model, compounding the device's diagnostic accuracy over time. That data flywheel strengthens the product's position against potential hardware competitors.
The TRISH-to-commercial pipeline PlenOptika represents offers a template for public and private investors evaluating dual-use health technology: research funding absorbed development risk, and the terrestrial market—not the space application—is where the scale lives.
